Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content

How is LSDs prevalence & epidemiology different in our region?

Global use of RAM and Thromboprophylaxis in hospitalized patients

Achievement of ESC/EAS LDL-C Treatment Goals After an ACS with Statin and Alirocumab

Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients

This systematic review and network meta-analysis revealed that the use of low-molecular-weight heparin (LMWH) may be more effective than unfractionated heparin (UFH) in reducing incidence of deep vein thrombosis (DVT) among critically ill patients.

LDL-C The Only Causal Risk Factor for ASCVD

Why low-density lipoprotein-cholesterol, the only causal risk factor for atherosclerotic cardiovascular disease, is still overlooked and underestimated.

Benefit of Prophylaxis for High-Risk Surgical Patients

Pompe

About Type 2 Inflammation – Nasal Polyps

Slowing of brain atrophy with Teriflunomide

APSC Consensus Recommendations on Dyslipidemia

Independent Risk Factors for Venous Thromboembolism

Specific Patient Characteristics Linked to Below Average Quality of Life in Patients with Recent Venous Thromboembolism (VTE)

Many associated factors are modifiable indicating potential benefit from planned strategies.